Mergers & Acquisitions Mergers & Acquisitions

Illumina, Grail arguments before US FTC focus on merger's impact on lives saved

Oral arguments by Illumina and Grail before the US Federal Trade Commission today focused on the competitive impact of the merger on lives saved through Grail’s cancer-detecting blood test, and on the parties’ proposed “open offer” to customers of its gene-sequencing platform.
The five commissioners heard arguments in the appeal

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Serafina Smith


Serafina Smith covers mergers and acquisitions for MLex from New York. Before becoming a journalist, Serafina was a paralegal supporting the United States Department of Justice, where she worked on foreign bribery and money laundering cases. She holds a master’s degree in journalism from New York University and a bachelor’s degree in linguistics from Georgetown University.

Discover MLex

Stay on top of global regulatory developments

Latest News